Newsroom
Strive to Deliver Breakthroughs
-
September 30, 2020
Harbour BioMed Announces Dosing of First Patient in Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 30, 2020. Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today ...
View more -
September 21, 2020
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
Cambridge, MA, Rotterdam, NL, Suzhou, CN – September 21, 2020. Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company ...
View more -
September 11, 2020
Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs
CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020. Cambridge, MA, Rotterdam, NL, Suzhou Xinxiang, ...
View more -
September 02, 2020
Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020
September, 2, 2020, Cambridge, MA, Rotterdam, NL, Shanghai, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, pr...
View more -
August 31, 2020
Harbour BioMed Will Present Its New Platform HBICE™ (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit
August, 31, 2020, Shanghai, China – Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented &nb...
View more -
August 24, 2020
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases
Cambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has enter...
View more -
August 21, 2020
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020
HBM’s Bispecific Antibody BCMA X CD3 (HBM7020) has a unique 2+1 format built by the proprietary fully human heavy chain only antibody derived fro...
View more -
August 19, 2020
Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19
Cambridge, MA, Rotterdam, NL, Suzhou CN – August 19, 2020. Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, tod...
View more -
July 31, 2020
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups
July 31, 2020 — Cambridge, MA, Rotterdam, NL, Suzhou, Shanghai, CN— Harbour BioMed (HBM) , a global clinical stage biopharmaceutical company and Vi...
View more -
July 16, 2020
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 16th, 2020. Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1